Eli Lilly's CFO explains why the company's newest weight loss drug Zepbound will cost 20% less than the current options

Zepbound is expected to be available in the U.S. by the end of the year.

Related Keywords

,Roka Bioscience ,Eli Lilly ,Evan David Seigerman ,Jay Brogdon ,Novo Nordisk ,Warren Buffett ,Daniel Hobbs ,Novo Nordisk Ozempic ,Charlie Munger ,Cem Nurkan ,Mark Purcell ,Sheryl Estrada ,Lilly Mounjaro ,Matthew Hill ,Lars Boesgaard ,Simmons First National Corporation Nasdaq ,Regions Bank ,Communications Technology ,Berkshire Hathaway ,Drug Administration ,Biotechnology Corporation Nasdaq ,Morgan Stanley ,Enterprise Technology Research ,Morgan Stanley European Biopharmaceuticals ,Simmons First National Corporation ,Enterprise Technology Research Director ,Ceos ,Ufos ,Fo ,Ceo ,Chief Financial Officer ,Finance Chief ,Chief Financial Officers ,Ickstarter ,Ickstarter Amp 039s New Finance Chief Is Ultra Extroverted And She Credits That Trait To Her Success Asa People Centric Cfo ,Cindy Wilson ,Everette Taylor ,People Centric ,People ,Talent ,Ech Company ,